Sanofi to buy Inhibrx for $1.7 billion
PARIS, FRANCE: Sanofi, a global pharmaceutical company, has agreed to acquire Inhibrx, a clinical-stage biotech firm, for $30.0 per share in cash, or about $1.7 billion. The deal is subject to the spin-off of non-INBRX-101 assets into a new entity, New Inhibrx, which will be owned by Inhibrx’s shareholders and Sanofi. INBRX-101 is a novel…